Document Detail


Efavirenz: a review.
MedLine Citation:
PMID:  17425480     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combination regimens is good, as has been demonstrated in many clinical trials. Efavirenz has a long plasma half-life, which allows for once-daily dosing, but, as a consequence of this and the low genetic barrier, it is also prone to select for viral resistance when adherence to therapy is suboptimal. The most frequently encountered side effects are neuropsychiatric symptoms. These side effects are usually transient, but have been shown to persist for up to 2 years after initiation of therapy in some patients. This review outlines important and recent pharmacological and clinical data, which explain why efavirenz became a component of preferred treatment regimens today.
Authors:
Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  8     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-11     Completed Date:  2007-05-03     Revised Date:  2014-02-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  851-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Antiretroviral Therapy, Highly Active
Benzoxazines / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Clinical Trials as Topic
Drug Administration Schedule
Drug Interactions
Drug Resistance, Viral
HIV Infections / drug therapy*,  virology
HIV-1 / drug effects*,  enzymology
Humans
Reverse Transcriptase Inhibitors / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Benzoxazines; 0/Reverse Transcriptase Inhibitors; JE6H2O27P8/efavirenz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected pa...
Next Document:  LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus.